Literature DB >> 24670961

Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010.

.   

Abstract

PROBLEM/CONDITION: Autism spectrum disorder (ASD). PERIOD COVERED: 2010. DESCRIPTION OF SYSTEM: The Autism and Developmental Disabilities Monitoring (ADDM) Network is an active surveillance system in the United States that provides estimates of the prevalence of ASD and other characteristics among children aged 8 years whose parents or guardians live in 11 ADDM sites in the United States. ADDM surveillance is conducted in two phases. The first phase consists of screening and abstracting comprehensive evaluations performed by professional providers in the community. Multiple data sources for these evaluations include general pediatric health clinics and specialized programs for children with developmental disabilities. In addition, most ADDM Network sites also review and abstract records of children receiving special education services in public schools. The second phase involves review of all abstracted evaluations by trained clinicians to determine ASD surveillance case status. A child meets the surveillance case definition for ASD if a comprehensive evaluation of that child completed by a qualified professional describes behaviors consistent with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for any of the following conditions: autistic disorder, pervasive developmental disorder-not otherwise specified (including atypical autism), or Asperger disorder. This report provides updated prevalence estimates for ASD from the 2010 surveillance year. In addition to prevalence estimates, characteristics of the population of children with ASD are described.
RESULTS: For 2010, the overall prevalence of ASD among the ADDM sites was 14.7 per 1,000 (one in 68) children aged 8 years. Overall ASD prevalence estimates varied among sites from 5.7 to 21.9 per 1,000 children aged 8 years. ASD prevalence estimates also varied by sex and racial/ethnic group. Approximately one in 42 boys and one in 189 girls living in the ADDM Network communities were identified as having ASD. Non-Hispanic white children were approximately 30% more likely to be identified with ASD than non-Hispanic black children and were almost 50% more likely to be identified with ASD than Hispanic children. Among the seven sites with sufficient data on intellectual ability, 31% of children with ASD were classified as having IQ scores in the range of intellectual disability (IQ ≤70), 23% in the borderline range (IQ = 71-85), and 46% in the average or above average range of intellectual ability (IQ >85). The proportion of children classified in the range of intellectual disability differed by race/ethnicity. Approximately 48% of non-Hispanic black children with ASD were classified in the range of intellectual disability compared with 38% of Hispanic children and 25% of non-Hispanic white children. The median age of earliest known ASD diagnosis was 53 months and did not differ significantly by sex or race/ethnicity.
INTERPRETATION: These findings from CDC's ADDM Network, which are based on 2010 data reported from 11 sites, provide updated population-based estimates of the prevalence of ASD in multiple communities in the United States. Because the ADDM Network sites do not provide a representative sample of the entire United States, the combined prevalence estimates presented in this report cannot be generalized to all children aged 8 years in the United States population. Consistent with previous reports from the ADDM Network, findings from the 2010 surveillance year were marked by significant variations in ASD prevalence by geographic area, sex, race/ethnicity, and level of intellectual ability. The extent to which this variation might be attributable to diagnostic practices, underrecognition of ASD symptoms in some racial/ethnic groups, socioeconomic disparities in access to services, and regional differences in clinical or school-based practices that might influence the findings in this report is unclear. PUBLIC HEALTH ACTION: ADDM Network investigators will continue to monitor the prevalence of ASD in select communities, with a focus on exploring changes within these communities that might affect both the observed prevalence of ASD and population-based characteristics of children identified with ASD. Although ASD is sometimes diagnosed by 2 years of age, the median age of the first ASD diagnosis remains older than age 4 years in the ADDM Network communities. Recommendations from the ADDM Network include enhancing strategies to address the need for 1) standardized, widely adopted measures to document ASD severity and functional limitations associated with ASD diagnosis; 2) improved recognition and documentation of symptoms of ASD, particularly among both boys and girls, children without intellectual disability, and children in all racial/ethnic groups; and 3) decreasing the age when children receive their first evaluation for and a diagnosis of ASD and are enrolled in community-based support systems.

Entities:  

Mesh:

Year:  2014        PMID: 24670961

Source DB:  PubMed          Journal:  MMWR Surveill Summ        ISSN: 1545-8636


  878 in total

1.  Increased Prevalence of Unusual Sensory Behaviors in Infants at Risk for, and Teens with, Autism Spectrum Disorder.

Authors:  Hannah M Van Etten; Maninderjit Kaur; Sudha M Srinivasan; Shereen J Cohen; Anjana Bhat; Karen R Dobkins
Journal:  J Autism Dev Disord       Date:  2017-11

2.  Increasing adaptive behavior skill deficits from childhood to adolescence in autism spectrum disorder: role of executive function.

Authors:  Cara E Pugliese; Laura Anthony; John F Strang; Katerina Dudley; Gregory L Wallace; Lauren Kenworthy
Journal:  J Autism Dev Disord       Date:  2015-06

3.  A Response to Papatola and Lustig's Paper on Navigating a Managed Care Peer Review: Guidance for Clinicians Using Applied Behavior Analysis in the Treatment of Children on the Autism Spectrum.

Authors:  Julie Kornack; Brandon Herscovitch; Ashley L Williams
Journal:  Behav Anal Pract       Date:  2017-05-22

4.  A Mixed Methods Study of Barriers to Formal Diagnosis of Autism Spectrum Disorder in Adults.

Authors:  Laura Foran Lewis
Journal:  J Autism Dev Disord       Date:  2017-08

5.  Differing Developmental Trajectories in Heart Rate Responses to Speech Stimuli in Infants at High and Low Risk for Autism Spectrum Disorder.

Authors:  Katherine L Perdue; Laura A Edwards; Helen Tager-Flusberg; Charles A Nelson
Journal:  J Autism Dev Disord       Date:  2017-08

6.  Delayed Diagnosis and Treatment Among Children with Autism Who Experience Adversity.

Authors:  Kristin L Berg; Kruti Acharya; Cheng-Shi Shiu; Michael E Msall
Journal:  J Autism Dev Disord       Date:  2018-01

7.  Replication and Comparison of the Newly Proposed ADOS-2, Module 4 Algorithm in ASD Without ID: A Multi-site Study.

Authors:  Cara E Pugliese; Lauren Kenworthy; Vanessa Hus Bal; Gregory L Wallace; Benjamin E Yerys; Brenna B Maddox; Susan W White; Haroon Popal; Anna Chelsea Armour; Judith Miller; John D Herrington; Robert T Schultz; Alex Martin; Laura Gutermuth Anthony
Journal:  J Autism Dev Disord       Date:  2015-12

Review 8.  Meta-Analysis of the Association between GABA Receptor Polymorphisms and Autism Spectrum Disorder (ASD).

Authors:  Manijeh Mahdavi; Majid Kheirollahi; Roya Riahi; Fariborz Khorvash; Mehdi Khorrami; Maryam Mirsafaie
Journal:  J Mol Neurosci       Date:  2018-05-03       Impact factor: 3.444

9.  Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide.

Authors:  Gregory L Holmes; Chengju Tian; Amanda E Hernan; Sean Flynn; Devon Camp; Jeremy Barry
Journal:  Neurobiol Dis       Date:  2015-03-10       Impact factor: 5.996

Review 10.  Neuroimaging-based methods for autism identification: a possible translational application?

Authors:  Alessandra Retico; Michela Tosetti; Filippo Muratori; Sara Calderoni
Journal:  Funct Neurol       Date:  2014 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.